scholarly journals Clinical Relevance of Circulating Nucleic Acids in Blood of Prostate Cancer Patients

Author(s):  
Heidi Schwarzenbach
The Prostate ◽  
2007 ◽  
Vol 67 (4) ◽  
pp. 427-432 ◽  
Author(s):  
Jochen Reibenwein ◽  
Dietmar Pils ◽  
Peter Horak ◽  
Birgit Tomicek ◽  
Gregor Goldner ◽  
...  

Author(s):  
Allen K. C. Chan ◽  
Rossa W. K. Chiu ◽  
Y. M. Dennis Lo

There has recently been an upsurge of interest in the analysis of circulating nucleic acids (DNA and/or RNA) in blood plasma or serum as a clinical diagnostic tool. Occasional earlier reports suggested the existence of circulating nucleic acids, but the potential clinical implication was not realized until 1996, when DNA with tumour-specific characteristics was demonstrated in the plasma/serum of cancer patients. This finding opened up possibilities for non-invasive cancer diagnosis. Potential applications have been reported in cancer diagnosis, prenatal diagnosis, transplantation and traumatology. Some of the findings are on the verge of being translated into clinical use. DNA is also now being sought in other body fluids such as urine.


2005 ◽  
Vol 21 (3) ◽  
pp. 105-120 ◽  
Author(s):  
Georg Goebel ◽  
Marion Zitt ◽  
Matthias Zitt ◽  
Hannes M. Müller

It is now widely accepted that there is a need for the development of molecular markers of cancer that can be used for clinical prognostication and monitoring. Approximately a decade ago tumor-derived circulating nucleic acids in the plasma or serum (CNAPS) of cancer patients were introduced as a noninvasive tool for cancer detection. This review focuses on the various types of CNAPS of patients with solid neoplasias (genetic alterations in circulating DNA, microsatellites, methylated DNA, viral DNA, nucleosomes, mitochondrial DNA and cell-free mRNA) and their putative potential as prognostic or predictive parameter or even as a tool for therapy monitoring during follow-up. Additionally, this review aims to point out the difference between a prognostic and a predictive factor in patient bloodstream. However, with rapid technical improvement and well-designed studies we conclude that the next years will see CNAPS analysis integrated in the prognostication and monitoring of cancer patients, thus producing more specific treatment regimens for patients with various stages of neoplastic disease and ultimately longer survival and better quality of life.


Author(s):  
Claire E. Fletcher ◽  
Ailsa Sita-Lumsden ◽  
Akifumi Shibakawa ◽  
Charlotte L. Bevan

2013 ◽  
Vol 7 (6) ◽  
pp. 867-877 ◽  
Author(s):  
Ailsa Sita-Lumsden ◽  
Claire E Fletcher ◽  
D Alwyn Dart ◽  
Greg N Brooke ◽  
Jonathan Waxman ◽  
...  

2009 ◽  
Vol 15 (3-4) ◽  
pp. 101-114 ◽  
Author(s):  
Zacharoula Panteleakou ◽  
Peter Lembessis ◽  
Antigone Sourla ◽  
Nikolaos Pissimissis ◽  
Aristides Polyzos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document